Building the Leading Extracellular Protein Degradation Company

We are using our proprietary LYTAC (lysosomal targeting chimeras) Platform to discover and develop first-in-class therapeutics that degrade extracellular and membrane-bound proteins. Our LYTAC degraders have the potential to drive a range of difficult-to-treat diseases, including cancers and autoimmune conditions.

Founded in 2019, we are privately held and backed by a syndicate of blue-chip investors. We are headquartered and have laboratory space in the thriving South San Francisco biotech hub.

LYTAC binding to receptor on the cell surface

About our
Founding

In July 2020, Carolyn Bertozzi, Ph.D. and her team at Stanford University published a transformational paper that characterized a new class of molecules called lysosome-targeting chimeras, or LYTACs. In the paper, Dr. Bertozzi and her team described a new method of engineering an antibody to shuttle a targeted extracellular protein into the lysosome, a cellular component inherently responsible for degradation. Versant Ventures subsequently licensed the technology, and Lycia, ultimately, was born.

Read Dr. Bertozzi’s original paper on LYTACs and learn how Lycia has continued to evolve this novel technology to expand its potential applications.

Learn more about our platform.

Our Team

We are led by a team of seasoned industry executives who bring a mix of emerging biotech and large pharma experience and expertise. Our Board of Directors and Scientific Advisory Board comprise renowned industry leaders and academic visionaries whose strategic guidance and insights are helping support the growth of our company and advancement of our pipeline.

William J. Rieflin

Chair, Lycia’s Board of Directors
Executive Chair, NGM Biopharmaceuticals

Bio

Tim Anderson

Partner, Head of Research, Cowen Healthcare Investments

Bio

Ming Fang

Managing Director, Redmile Group

Bio

Laurent Fischer, M.D.

President and Chief Executive Officer, Adverum Biotechnologies

Bio

Clare Ozawa, Ph.D.

Managing Director, Versant Ventures

Bio

Aetna Wun Trombley, Ph.D.

President and Chief Executive Officer

Bio

Tom Woiwode, Ph.D.

Managing Director, Versant Ventures

Bio

Carolyn Bertozzi, Ph.D.

Academic Founder, Lycia
Chair, Scientific Advisory Board

Professor of Chemistry, Stanford University
Investigator, Howard Hughes Medical Institute

Professor Bertozzi is the Anne T. and Robert M. Bass Professor of Chemistry and Professor of Chemical & Systems Biology and Radiology at Stanford University, and an Investigator of the Howard Hughes Medical Institute. She completed her undergraduate degree in chemistry from Harvard University in 1988 and her doctorate in chemistry from University of California, Berkeley, in 1993. After completing postdoctoral work at University of California, San Francisco, in the field of cellular immunology, she joined the UC Berkeley faculty in 1996.

In June 2015, she joined the faculty at Stanford University coincident with the launch of Stanford’s Chemistry, Engineering & Medicine for Human Health (ChEM-H) Institute. Professor Bertozzi’s research interests span the disciplines of chemistry and biology with an emphasis on studies of cell surface glycosylation pertinent to disease states. Her lab focuses on profiling changes in cell surface glycosylation associated with cancer, inflammation and bacterial infection, and exploiting this information for development of diagnostic and therapeutic approaches, most recently in the area of immuno-oncology. She has been recognized with many honors and awards for her research accomplishments.

She is an elected member of the Institute of Medicine, National Academy of Sciences, and American Academy of Arts and Sciences. She has been awarded the Lemelson-MIT Prize, the Heinrich Wieland Prize and a MacArthur Foundation Fellowship, among many others.

Carolyn Bertozzi, Ph.D.

Professor of Chemistry, Stanford University
Investigator, Howard Hughes Medical Institute
Chair, Lycia Scientific Advisory Board
Bio

Monther Abu-Remaileh, Ph.D.

Assistant Professor of Chemical Engineering, Stanford University
Bio

Mark M. Davis, Ph.D.

Professor of Microbiology and Immunology, Stanford University
Investigator, Howard Hughes Medical Institute
Bio

Randy Schekman, Ph.D.

Professor of Cell and Developmental Biology, University of California at Berkeley
Investigator, Howard Hughes Medical Institute
Bio

Alanna Schepartz, Ph.D.

Professor of Molecular and Cell Biology, University of California at Berkeley
Bio

Daniel Van Hoff, M.D.

Distinguished Professor at the Translational Genomics Research Institute
Bio

Our Investors

“Lycia’s focus on the untapped extracellular proteome and the potential to leverage the LYTAC platform across therapeutic modalities, including small molecules and antibodies, has the potential to transform the protein degradation field.”

Clare Ozawa, Ph.D.
Managing Director, Versant Ventures